pharma · Ovarian Cancer · Breast Cancer · ZNTL
Zentalis Pharmaceuticals
Zentalis Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 10275 Science Center Dr, Suite 200, San Diego, California 92121, US
- Employees
- 123
- Programs
- 14
- Drugs
- 4
- Patents
- 0
Zentalis Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Zentalis Pharmaceuticals.
Zentalis Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Azenosertib
Zentalis Pharmaceuticals
Uterine Serous Carcinoma
2 trials -
Azenosertib
Zentalis Pharmaceuticals
Ovarian Cancer
1 trial -
Azenosertib
Zentalis Pharmaceuticals
Breast Cancer
1 trial -
ZN-d5
Zentalis Pharmaceuticals
Amyloidosis
1 trial -
ZN-d5 ZN-c3
Zentalis Pharmaceuticals
Acute Myeloid Leukemia (AML)
1 trial -
Zentalis
Zentalis Pharmaceuticals
Advanced Pancreatic Adenocarcinoma
1 trial -
azenosertib
Zentalis Pharmaceuticals
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
1 trial
Frequently asked questions
How many clinical projects does Zentalis Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.